Improvement of osteogenic differentiation potential of placenta-derived mesenchymal stem cells by metformin via AMPK pathway activation.

ABSTRACT:

Background

Placenta-derived human mesenchymal stem cells (PL-MSCs) have gained a lot of attention in the field of regenerative medicine due to their availability and bone-forming capacity. However, the osteogenic differentiation capacity of these cells remains inconsistent and could be improved to achieve greater efficiency. Although metformin, a widely used oral hypoglycemic agent, has been shown to increase bone formation in various cell types, its effect on osteogenic differentiation of PL-MSCs has not yet been investigated. Therefore, the objective of this study was to examine the effect of metformin on the osteogenic differentiation capacity of PL-MSCs and the underlying mechanisms.

Methods

The PL-MSCs were treated with 0.5 to 640 µM metformin and their osteogenic diffe

SUBMITTER: Manochantr S 

PROVIDER: S-EPMC11559138 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature